Antagonizing CD105 enhances radiation sensitivity in prostate cancer

Anisha Madhav, Allen Andres, Frank Duong, Rajeev Mishra, Subhash Haldar, Zhenqiu Liu, Bryan Angara, Roberta Gottlieb, Zachary S. Zumsteg, Neil A. Bhowmick

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Radiation therapy is the primary intervention for nearly half of the patients with localized advanced prostate cancer and standard of care for recurrent disease following surgery. The development of radiation-resistant disease is an obstacle for nearly 30–50% of patients undergoing radiotherapy. A better understanding of mechanisms that lead to radiation resistance could aid in the development of sensitizing agents to improve outcome. Here we identified a radiation-resistance pathway mediated by CD105, downstream of BMP and TGF-β signaling. Antagonizing CD105-dependent BMP signaling with a partially humanized monoclonal antibody, TRC105, resulted in a significant reduction in clonogenicity when combined with irradiation. In trying to better understand the mechanism for the radio-sensitization, we found that radiation-induced CD105/BMP signaling was sufficient and necessary for the upregulation of sirtuin 1 (SIRT1) in contributing to p53 stabilization and PGC-1α activation. Combining TRC105 with irradiation delayed DNA damage repair compared to irradiation alone. However, in the absence of p53 function, combining TRC105 and radiation resulted in no reduction in clonogenicity compared to radiation alone, despite similar reduction of DNA damage repair observed in p53-intact cells. This suggested DNA damage repair was not the sole determinant of CD105 radio-resistance. As cancer cells undergo an energy deficit following irradiation, due to the demands of DNA and organelle repair, we examined SIRT1’s role on p53 and PGC-1α with respect to glycolysis and mitochondrial biogenesis, respectively. Consequently, blocking the CD105-SIRT1 axis was found to deplete the ATP stores of irradiated cells and cause G2 cell cycle arrest. Xenograft models supported these findings that combining TRC105 with irradiation significantly reduces tumor size over irradiation alone (p value = 10 −9 ). We identified a novel synthetic lethality strategy of combining radiation and CD105 targeting to address the DNA repair and metabolic addiction induced by irradiation in p53-functional prostate cancers.

Original languageEnglish (US)
Pages (from-to)4385-4397
Number of pages13
JournalOncogene
Volume37
Issue number32
DOIs
StatePublished - Aug 9 2018

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Genetics
  • Cancer Research

Fingerprint Dive into the research topics of 'Antagonizing CD105 enhances radiation sensitivity in prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    Madhav, A., Andres, A., Duong, F., Mishra, R., Haldar, S., Liu, Z., Angara, B., Gottlieb, R., Zumsteg, Z. S., & Bhowmick, N. A. (2018). Antagonizing CD105 enhances radiation sensitivity in prostate cancer. Oncogene, 37(32), 4385-4397. https://doi.org/10.1038/s41388-018-0278-0